Rising temperatures and climate change may increase default risks in 30% of agricultural and housing loans in the next five ...

ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...

BCG predicts rising temperatures will increase default risk in 30% of agri and housing loans by 2030, highlighting climate ...

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in Europe in patients with ...

A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials.

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...

UroGen Pharma has opened another front in its attack on bladder cancer, paying IconOVir Bio $4 million in stock for an early-phase oncolytic virus that could work like a turbocharged Bacillus Calmette ...

Researchers from Australia have developed a groundbreaking mRNA vaccine against tuberculosis (TB), showing promising results in pre-clinical mouse trials. This innovative vaccine could outperform the ...

A beverage company thinks like a startup to maintain a closer connection with its customers. That’s the word from a recent episode of MIT’s and BCG’s Me, Myself, and AI, which featured Ronald den ...

ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...

Coding assistance and completion tools saved developers around 4 million hours last year, the retailer said during an ...